Your session is about to expire
← Back to Search
Penile Prosthesis
Inflatable Penile Prosthesis for Erectile Dysfunction
N/A
Recruiting
Led By Paul Perito, MD
Research Sponsored by Rigicon, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights
No Placebo-Only Group
Summary
This trial evaluates the long-term safety and effectiveness of a surgically implanted device called Rigicon Infla 10® for men with erectile dysfunction. The device helps men achieve an erection by inflating chambers in the penis. The study will follow patients for an extended period after implantation. This type of device has been used since 1974 to treat erectile dysfunction, with long-term success and high patient satisfaction.
Who is the study for?
Men over 21 with erectile dysfunction can join this trial if they agree to use the Rigicon Infla10® prosthesis as treatment, can follow up on visits and tests, and have no allergies to device materials. Exclusions include those with anesthesia risks, previous penile surgeries, infections at surgery site or systemic infections, limited manual dexterity or mental capacity for device operation, life expectancy under two years, uncontrolled diabetes or significant other health issues.
What is being tested?
The study is testing the safety and effectiveness of the Rigicon Infla10® Three-Piece Inflatable Penile Prosthesis in men with erectile dysfunction over a period of up to three years post-implantation. Participants will be monitored regularly following institutional standards for managing ED and any related conditions.
What are the potential side effects?
Potential side effects may include pain at implant site, infection risk increase due to surgery, mechanical failure of the prosthesis leading to additional interventions or removals. Individual experiences may vary based on personal health factors.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 36 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Rigidity at 12 months
Survival at 12 months
Secondary study objectives
Serious complications
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Experimental: Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis GroupExperimental Treatment1 Intervention
Male subjects 21 years of age and older who are implanted with an Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis for erectile dysfunction.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Erectile Dysfunction (ED) include PDE5 inhibitors, vacuum erection devices, penile injections, and penile prostheses. PDE5 inhibitors, such as sildenafil, work by enhancing blood flow to the penis by inhibiting the enzyme phosphodiesterase type 5.
Vacuum erection devices create an erection by using vacuum pressure to increase blood flow into the penis and occlusive rings to maintain it. Penile injections involve injecting vasodilating agents directly into the penile tissue to induce an erection.
Inflatable penile prostheses, like the Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis, enable an erection by manually pumping fluid into cylinders implanted in the penis, mimicking a natural erection. These treatments are crucial for ED patients as they offer various options to restore sexual function, improve quality of life, and enhance psychological well-being.
Life quality change after inflatable penile prosthesis implantation.Post-prostatectomy erectile dysfunction: contemporary approaches from a US perspective.
Life quality change after inflatable penile prosthesis implantation.Post-prostatectomy erectile dysfunction: contemporary approaches from a US perspective.
Find a Location
Who is running the clinical trial?
Rigicon, Inc.Lead Sponsor
Paul Perito, MDPrincipal InvestigatorPerito Urology - Penile Implant Clinic
Duygu Kirkik, PhDStudy ChairRigicon, Inc.
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a bleeding disorder that may make procedures unsafe for me.I have been diagnosed with a fibrotic condition affecting my reproductive organs.You are willing to complete all protocol required follow-up visits and tests.I have been diagnosed with reduced sensation in my penis.I have a compromised immune system due to conditions like lupus or scleroderma.I am a man aged 21 or older.I have had surgery for penile prosthesis or enlargement before.I do not have any active infections, especially in the area where surgery is planned.I do not have any major health issues that could affect the study's safety or results.I have been diagnosed with erectile dysfunction.My fasting blood sugar is not over 300 on the morning of surgery.I can communicate clearly and understand the study's requirements.I agree to use Infla10® three-piece IPP for erectile dysfunction treatment.I cannot have general anesthesia due to health risks.I agree to use Infla10® as treatment for erectile dysfunction.I am a man aged 21 or older.I have been diagnosed with erectile dysfunction.
Research Study Groups:
This trial has the following groups:- Group 1: Experimental: Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis Group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger